Advertisement

InVivo Therapeutics seeks FDA humanitarian use device exemption for its biopolymer scaffolding product in treatment of non-severing spinal cord injuries.

invivo logo

InVivo Therapeutics (OTC:NVIV) is seeking FDA approval for a humanitarian use device designation for its biopolymer scaffolding product in treatment of traumatic spinal cord injuries.

The Cambridge, Mass.-based firm expects to begin a clinical trial of the scaffolding in acute spinal cord injuries early next year.

Advertisement
Advertisement